Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To explore the efficacy and safety of minimally invasive suprachoroidal drainage for the treatment of advanced neovascular glaucoma
To explore the efficacy and safety of minimally invasive supraporcular drainage in the treatment of advanced neovascular glaucoma, and to record the various basic diseases, ocular conditions, lifestyle, inflammatory markers and other parameters of NVG patients. To compare the safety and efficacy of new surgical methods and traditional surgical methods in order to find an effective treatment for neovascular glaucoma
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Surgical Treatment Group | Experimental | The patient will undergo a minimally invasive suprachoroidal drainage procedure |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| minimally invasive suprachoroidal drainage | Procedure | minimally invasive suprachoroidal drainage |
|
| Measure | Description | Time Frame |
|---|---|---|
| Ocular biological parameters | intraocular pressure | 1 day, 1 week, 1 month, 3 months, and 6 months after surgery |
| Ocular biological parameters | visual acuity | 1 day, 1 week, 1 month, 3 months, and 6 months after surgery |
| Surgical outcome measures | use of intraocular pressure lowering drugs | 1 day, 1 week, 1 month, 3 months, and 6 months after surgery |
| The success rate of surgery was evaluated according to the specific value of intraocular pressure after surgery | Complete success was defined as IOP within the normal range with no drug dependence, conditional success was defined as IOP within the normal range with drug dependence, and failure was defined as the rest | 1 day, 1 week, 1 month, 3 months, and 6 months after surgery |
| Measure | Description | Time Frame |
|---|---|---|
| The effective rate of surgery was evaluated according to the amplitude of IOP reduction after surgery and the change in the number of IOP-lowering drugs | Amplitude of IOP reduction: IOP change/initial IOP.The total number of IOP lowering drugs was recorded based on the number of active ingredients | 1 day, 1 week, 1 month, 3 months, and 6 months after surgery |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Zhongnan Hospital of Wuhan University | Wuhan | Hubei | 430071 | China |
Not provided
| ID | Term |
|---|---|
| D015355 | Glaucoma, Neovascular |
| D012170 | Retinal Vein Occlusion |
| D003930 | Diabetic Retinopathy |
| ID | Term |
|---|---|
| D005901 | Glaucoma |
| D009798 | Ocular Hypertension |
| D005128 | Eye Diseases |
| D012164 | Retinal Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Surgical outcome measures | complications | 1 day, 1 week, 1 month, 3 months, and 6 months after surgery |
| D020246 |
| Venous Thrombosis |
| D013927 | Thrombosis |
| D016769 | Embolism and Thrombosis |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
| D003925 | Diabetic Angiopathies |
| D048909 | Diabetes Complications |
| D003920 | Diabetes Mellitus |
| D004700 | Endocrine System Diseases |